New CEO for Merz Therapeutics: Stefan König
As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as CEO and Managing Director. As one of the businesses of Merz Group, Merz Therapeutics provides medical solutions for the treatment of serious health conditions such as neurological health impairments or diseases of the liver.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005731/en/
Stefan Koenig, CEO Merz Therapeutics (Photo: Business Wire)
Stefan König is an accomplished leader who has successfully worked in the pharmaceutical industry for his entire career, both at national and international market level. “Merz Therapeutics has had a successful development in last years. That is why we are very pleased to have won an exceptional executive with Stefan König who will continue to expand our business and take it to the next level. His profound expert knowledge in both clinical-stage drug development and commercialization as well as his experience in different global markets make him the ideal person to drive the future growth strategy of Merz Therapeutics,” says Phillip Burchard, CEO of the Merz Group and Chairman of the Merz Holding Board.
Until recently, Stefan König held the position of President and CEO of George Medicines, a London-based company focusing on the development of pharmaceuticals in an advanced clinical phase. George Medicines is a spin-off of the George Institute, one of the leading international health research institutes. Before this, Stefan König worked for many years at Takeda Pharmaceuticals, where he held various senior positions in global, regional and local functions. Among others, he was responsible for the global Inflammatory Bowel Disease franchise, after heading up a number of local and regional market organizations.
After a strategic reorganization three years ago, Merz Group created Merz Therapeutics as one of its three core businesses, with the goal for each of the individual businesses to have a better focus on specific customers and markets. Since then, Merz Therapeutics has developed favourably. The previous CEO and Managing Director of Merz Therapeutics, Stefan Brinkmann, is leaving Merz by best mutual agreement at the end of February after many years. With Stefan König’s appointment as of March 1, 2023, we will ensure a seamless transition.
About the Merz Group
The Merz Group is a global, diversified health care company based in Frankfurt, Germany. Family-owned for over 110 years, the company is distinguished by its commitment to innovation, a long-term perspective, and a focus on sustainable, profitable growth. The Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 3,730 people (as of financial year 21/22) in 28 countries worldwide. To learn more, please visit www.merz.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005731/en/
Contact information
Merz Pharma GmbH & Co. KGaA
Communications
Karolina Dzeko-Balke
Telephone number: +49 (0) 69 1503 2749
E-mail: karolina.dzeko-balke@merz.de
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Norges Bank Terminates Its Observation On Kirin Holdings23.3.2023 06:00:00 CET | Press release
Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer. 1. Background Based on a recommendation of Norway’s Council on Ethics*1, Norges Bank placed Kirin Holdings under observation with the possibility of exclusion from its Government Pension Fund Global in March 2021*2. Following Kirin Holdings’ decision on the withdrawal from the Myanmar business in February 2022 and the basic agreement on the share transfer of the local joint venture Myanmar Brewery Limited in June 2022, Kirin Holdings announced the completion of the share transfer on January 23, 2023*3. Again, based on the recommendation of the Council on Ethics*4, Norges Bank terminated its observation on Kirin Holdings on March 22 2023*5. In addition, the following measures have been agreed upon to take to ensure the treatment of local employees. (1) Ensure freedom o
Hyundai Motor Company and Advent Technologies Sign Joint Development Agreement Following Successful Fuel Cell Technology Assessment23.3.2023 01:25:00 CET | Press release
Hyundai Motor Company today announced a successful technology assessment with Advent Technologies Holdings, Inc. (“Advent”), an innovation-driven leader in the fuel cell and hydrogen technology sectors. The assessment evaluated Advent's proprietary Membrane Electrode Assembly (“MEA”) technology for supplying Hyundai’s high-temperature fuel cell needs, and following its success, the two companies have entered into a Joint Development Agreement (“JDA”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005788/en/ From left to right: Seung Hyun Hong, Ph.D. (Vice President, Materials Research & Engineering Center, Hyundai), Jim Coffey (Chief Operating Officer & General Counsel, Advent Technologies) (Photo: Business Wire) The signing ceremony took place on March 22, 2023, at Advent’s headquarters in Charlestown, Massachusetts, and included senior executives from both companies. Under the agreement, Hyundai and Advent will work
Bentley Systems Announces Strategic Agreement with Worldsensing22.3.2023 21:01:00 CET | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has entered into a non-exclusive commercial agreement to strategically accelerate the adoption of Infrastructure IoT, further unlocking value for infrastructure designers, constructors, and owner-operators in their use of infrastructure digital twins. To this end, Worldsensing is acquiring from Bentley sensemetrics’ Thread connectivity device business to expand its hardware portfolio offerings. Bentley also becomes the lead investor in Worldsensing’s Series D capital raise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005676/en/ Worldsensing’s Connectivity Devices fully integrated with Bentley’s sensemetrics software and iTwin IoT cloud services. Image courtesy of Worldsensing. Worldsensing’s acquisition of the Thread connectivity device business will offer new options to its customers where adaptive senso
Incyte Announces FDA Approval of Zynyz ™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)22.3.2023 18:14:00 CET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). The Biologics License Application (BLA) for Zynyz for this indication has been approved under accelerated approval by the U.S. FDA based on tumor response rate and duration of response (DOR). Continued approval of Zynyz for this indication may be contingent on verification and description of clinical benefit in confirmatory trials. MCC is a rare and aggressive type of skin cancer that frequently appears as a single, painless, reddish-purple skin nodule on the head, neck and arms in skin exposed to sunlight1. MCC tends to grow quickly and has a high rate of metastatic disease, leading to a poor prognosis2,3. The estimated five-year overall survival (OS) rate is 14% in patients with MC
Mary Kay Highlights the Importance of Women’s Leadership and Private Sector Engagement in Conservation at the World Ocean Summit 2023 Hosted by Economist Impact22.3.2023 17:02:00 CET | Press release
Mary Kay Inc., a global advocate for corporate sustainability and signatory to the UN Global Compact Sustainable Ocean Principles, continues to play an important role in ocean conservation. In February, the beauty brand launched a groundbreaking, user-friendly platform offering valuable guidance, decision-support tools, and practical knowledge for marine practitioners. Following the announcement, Mary Kay recently participated at the 10th World Ocean Summit and Expo 2023 in Lisbon, Portugal, organized by Economist Impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230322005544/en/ Sandra Silva, Mary Kay Portugal’s General Manager participates on a panel on the topic of "Putting Coral Reef Restoration at the Heart of Ocean Conservation Action" at the World Ocean Summit in Lisbon, Portugal (Credit: Mary Kay Inc.). The World Ocean Summit is an annual global event that brings together the widest cross-section of the ocean co